-
公开(公告)号：US12172986B2
公开(公告)日：2024-12-24
申请号：US17059635
申请日：2019-05-31
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US10889866B2
公开(公告)日：2021-01-12
申请号：US15755225
申请日：2016-08-30
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Lihua Yu , Kian Huat Lim , Jacob D. Feala , Silvia Buonamici , Yoshiharu Mizui , Peter G. Smith , Ping Zhu , Eunice Sun Park , Michael W. Seiler , Marco Peter Fekkes
IPC: C12Q1/6886 , A61P35/00 , A61K31/4545 , A61K31/495 , A61K31/55 , C12Q1/02 , C12Q1/6806 , C12Q1/6841
Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
-
公开(公告)号：US11998544B2
公开(公告)日：2024-06-04
申请号：US17059876
申请日：2019-05-31
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , James Palacino , Michael Seiler , Ping Zhu , Evan Barry , Lihua Yu
IPC: A61K31/496 , A61K35/17 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/00 , A61K39/39 , A61K39/395 , A61K47/68
CPC classification number: A61K31/496 , A61K35/17 , A61K38/191 , A61K38/2013 , A61K38/2066 , A61K38/208 , A61K38/2086 , A61K38/217 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K47/6803 , A61K2039/6031 , A61K2039/6037 , A61K2039/6056 , A61K2039/6081
Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.
-
公开(公告)号：US11761045B2
公开(公告)日：2023-09-19
申请号：US17098940
申请日：2020-11-16
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Lihua Yu , Kian Huat Lim , Jacob D. Feala , Silvia Buonamici , Yoshiharu Mizui , Peter G. Smith , Ping Zhu , Eunice Sun Park , Michael W. Seiler , Marco Peter Fekkes
IPC: C12Q1/6886 , A61P35/00 , A61K31/4545 , A61K31/495 , A61K31/55 , C12Q1/02 , C12Q1/6806 , C12Q1/6841
CPC classification number: C12Q1/6886 , A61K31/4545 , A61K31/495 , A61K31/55 , A61P35/00 , C12Q1/025 , C12Q1/6806 , C12Q1/6841 , C12Q2600/106 , C12Q2600/158
Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
-
公开(公告)号：US09481669B2
公开(公告)日：2016-11-01
申请号：US14710687
申请日：2015-05-13
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Gregg F. Keaney , John Wang , Baudouin Gerard , Kenzo Arai , Xiang Liu , Guo Zhu Zheng , Kazunobu Kira , Parcharee Tivitmahaisoon , Sudeep Prajapati , Nicholas C. Gearhart , Yoshihiko Kotake , Satoshi Nagao , Regina Mikie Kanada Sonobe , Masayuki Miyano , Norio Murai , Silvia Buonamici , Lihua Yu , Eunice Sun Park , Betty Chan , Peter G. Smith , Michael P. Thomas , Ermira Pazolli , Kian Huat Lim
IPC: C07D405/06 , C07D405/14 , A61K31/496
CPC classification number: C07D405/14 , C07D405/06
Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.
Abstract translation: 本发明提供新颖的扁桃苷内酰吡啶化合物，含有这些化合物的药物组合物，以及使用该化合物作为治疗剂的方法。 这些化合物可用于治疗癌症，特别是癌症，其中靶向剪接体的试剂和其中的突变已知是有用的。
-
Patent Agency Ranking
公开(公告)号：US11352348B2
公开(公告)日：2022-06-07
申请号：US17247117
申请日：2020-11-30
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61P35/00 , A61K47/68 , A61K47/60 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US10745387B2
公开(公告)日：2020-08-18
申请号：US15529798
申请日：2016-11-17
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Gregg F. Keaney , John Wang , Baudouin Gerard , Kenzo Arai , Xiang Liu , Guo Zhu Zheng , Kazunobu Kira , Parcharee Tivitmahaisoon , Sudeep Prajapati , Nicholas C. Gearhart , Yoshihiko Kotake , Satoshi Nagao , Regina Mikie Kanada Sonobe , Masayuki Miyano , Norio Murai , Silvia Buonamici , Lihua Yu , Eunice Sun Park , Betty Chan , Peter G. Smith , Michael P. Thomas , Ermira Pazolli , Kian Huat Lim , Atsushi Endo , Arani Chanda
IPC: A61K31/496 , C07D295/182 , C07D405/14 , C07D405/06 , A61P35/02
Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
-
公开(公告)号：US20180318312A1
公开(公告)日：2018-11-08
申请号：US15755225
申请日：2016-08-30
Applicant: Lihua YU , Kian Huat LIM , Jacob D. FEALA , Silvia BUONAMICI , Yoshiharu MIZUI , Peter G. SMITH , Ping ZHU , Eunice Sun PARK , Michael W. SEILER , Marco Peter FEKKES , Eisai R&D Management Co., Ltd.
Inventor： Lihua Yu , Kian Huat Lim , Jacob D. Feala , Silvia Buonamici , Yoshiharu Mizui , Peter G. Smith , Ping Zhu , Eunice Sun Park , Michael W. Seiler , Marco Peter Fekkes
IPC: A61K31/55 , A61P35/00 , A61K31/4545 , A61K31/495 , C12Q1/6886 , C12Q1/02
CPC classification number: A61K31/55 , A61K31/4545 , A61K31/495 , A61P35/00 , C12Q1/025 , C12Q1/6806 , C12Q1/6841 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158
Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
-
公开(公告)号：US11945807B2
公开(公告)日：2024-04-02
申请号：US17661909
申请日：2022-05-03
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC classification number: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20210130909A1
公开(公告)日：2021-05-06
申请号：US17098940
申请日：2020-11-16
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Lihua Yu , Kian Huat Lim , Jacob D. Feala , Silvia Buonamici , Yoshiharu Mizui , Peter G. Smith , Ping Zhu , Eunice Sun Park , Michael W. Seiler , Marco Peter Fekkes
IPC: C12Q1/6886 , A61P35/00 , A61K31/4545 , A61K31/495 , A61K31/55 , C12Q1/02 , C12Q1/6806
Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.019 seconds)
